Nature Medicine paper confirms clinical utility of liquid biopsies in routine care for lung cancer Cohort study finds significant OS benefit in NSCLC with targetable ctDNA alterations

Charles Rudin named cancer center director at MSK

Charles Rudin was appointed director of Memorial Sloan Kettering Cancer Center, effective June 1.

May 22, 2026

USC comparison study of leading targeted therapies for ALK+ lung cancer could lead to better treatment decisions

A head-to-head comparison of five leading treatments for anaplastic lymphoma kinase-positive non-small cell lung cancer could help oncologists fine-tune first-line TKI selection beyond what’s been seen in clinical trials alone, according to a study conducted by a team of researchers from the Keck School of Medicine of USC, the USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences and the USC Shaeffer Center for Health Policy & Economics have conducted.

May 22, 2026

Vol.52 No.20

Drugs & Targets

FDA grants priority review to Hyrnuo in first-line HER2-mutated NSCLC

FDA has granted Hyrnuo (sevabertinib) priority review status for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations in patients with no prior therapy.

May 22, 2026

Vol.52 No.20

Clinical Roundup

Despite breakthroughs, many go without treatment for metastatic lung cancer, MUSC study finds

About half of people diagnosed with metastatic non-small-cell lung cancer never receive treatment, despite advances in options over recent decades that have created meaningful improvements in lifespan and quality of life for many patients.

May 15, 2026

Vol.52 No.19

Clinical Roundup

65% of eligible lung cancer patients do not receive the most appropriate targeted therapies

Diaceutics has released research revealing a critical shift in precision medicine. Despite major advances in biomarker testing, nearly two-thirds of eligible patients with advanced non-small cell lung cancer in the U.S. are still not receiving the most appropriate treatment.

May 01, 2026

Vol.52 No.17

Drugs & Targets

FDA accepts NDA for zipalertinib for NSCLC with mutations

FDA has accepted a New Drug Application for zipalertinib for the treatment of patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy, with or without amivantamab. The Prescription Drug User Fee Act target action date is Feb. 27, 2027.

May 01, 2026

Vol.52 No.17

Nature Medicine paper confirms clinical utility of liquid biopsies in routine care for lung cancer

Cohort study finds significant OS benefit in NSCLC with targetable ctDNA alterations

YOU MAY BE INTERESTED IN

Charles Rudin named cancer center director at MSK

USC comparison study of leading targeted therapies for ALK+ lung cancer could lead to better treatment decisions

FDA grants priority review to Hyrnuo in first-line HER2-mutated NSCLC

Despite breakthroughs, many go without treatment for metastatic lung cancer, MUSC study finds

65% of eligible lung cancer patients do not receive the most appropriate targeted therapies

FDA accepts NDA for zipalertinib for NSCLC with mutations

Renew today!

Subscriber content

Never miss an issue!

Login